These results showed that circPTPN12 accelerated tumor growth and sunitinib resistance via the STAT3 pathway and stattic combined with sunitinib therapy reduced the growth rate and sunitinib resistance of tumors in vivo. This evidence concerns the gene STAT3 and neoplasm.